Sawai Receives Approval for Tadalafil Tablets
Osaka, Japan – February 19, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Tadalafil tablets (the branded product: Cialis®).
Tadalafil tablets are prescribed for the treatment of erectile dysfunction.
The products approved by MHLW on Feb. 19.
Product Name: TADALAFIL Tablets 10 mg CI [SAWAI], 20 mg CI [SAWAI]
Generic name: Tadalafil
Brand products: Cialis® Tablets 10 mg, 20 mg
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.
PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.
E-mail: koho@sawai.co.jp